© 2022 MJH Life Sciences and Urology Times. All rights reserved.
© 2022 MJH Life Sciences™ and Urology Times. All rights reserved.
March 15, 2022
“Obviously, patients benefit [from this regimen]. Not only can they enjoy longer life, but also their cancer is pretty much under control for a longer time, which is great,” says Karim Fizazi, MD, PhD
March 09, 2022
“I think results from this study introduce a new standard of care for patients with metastatic hormone-sensitive prostate cancer, where we clearly need to do better than what we're doing today, since the sequence of therapy seems to be less effective than hitting them hard upfront,” says Fred Saad, MD, FRCS.
March 01, 2022
“If you're going to be embarking upon triplet based therapy, as Arasens has now clearly demonstrated the potential advantage, having really healthy and productive and efficient conversations with your integrated cancer care team is paramount,” says Neal D. Shore, MD, FACS.
February 28, 2022
Investigators of a recent study presented at the 2022 ASCO Genitourinary Cancers Symposium reported favorable outcomes of pembrolizumab in patients with renal cell carcinoma at 30-month follow up.
In this interview, lead author Benjamin Lowentritt, MD, FACS, discusses why the findings of the study, "Attainment of early, deep prostate-specific antigen response in metastatic castration-sensitive prostate cancer: A comparison of patients initiated on apalutamide or enzalutamide," are so important in future counseling for mCSPC.
February 25, 2022
Long-term follow-up from the CheckMate 9ER trial continued to show that first-line treatment with nivolumab plus cabozantinib was associated with a health-related quality-of-life benefit over treatment with sunitinib in patients with advanced renal cell carcinoma .
February 24, 2022
Efficacy and safety data from the final analysis of the retrospective CaboCHECK trial support the use of cabozantinib in patients with advanced or metastatic renal cell carcinoma after progression on immunotherapy.
Despite missing the primary end point, avelumab did demonstrate notable clinical activity and a favorable safety profile in the phase 2 ARIES trial.
“I think the notable finding is the fact that the overall detection rate is very high, even at low PSA levels,” says David M. Schuster, MD, FACR.
February 23, 2022
“I do think that this helps inform how to choose an agent for this specific stage of the disease,” says Benjamin Lowentritt, MD, FACS.